secwatch / observer
8-K filed October 28, 2022, 7:59 PM ET ticker VTGN CIK 0001411685
other material confidence high sentiment neutral materiality 0.50

Vistagen shareholders approve reverse stock split authorization up to 1-for-30; bylaw amendment fails

Vistagen Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Vistagen Therapeutics, Inc. shareholders approved Approval of Discretionary Authorization to Implement a Reverse Stock Split at the 2022-10-28 meeting.

Proposal
reverse split
Outcome
passed
Meeting
2022-10-28
Exact text from the filing
Proposal No. 5 – Approval of Discretionary Authorization to Implement a Reverse Stock Split For Against Abstain Votes 104,229,120 25,372,666 4,016,453 The vote required to approve Proposal No. 5, discretionary authority for the Company’s Board of Directors (the “ Board ”) to have the option to implement a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (“ Common Stock ”), at a ratio of between 1-for-2 and 1-for-30 (the “ Reverse Split ”), with the exact ratio to be determined by the Board, and the filing of an amendment to the Company’s Restated and Amended Articles of Incorporation, as amended, with the Nevada Secretary of State to effect the Reverse Split at any time as the Board may deem necessary and advisable prior to October 14, 2023, the one-year anniversary of the initial date of the Company’s 2022 Annual Meeting of Stockholders (the “ Annual Meeting ”) (the “ Reverse Split Authorization ”), was the affirmative vote
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Vistagen Therapeutics, Inc. shareholders rejected Approval of an Amendment to the Company's Bylaws at the 2022-10-28 meeting.

Proposal
charter amendment
Outcome
failed
Meeting
2022-10-28
Exact text from the filing
Proposal No. 6 – Approval of an Amendment to the Company ’ s Bylaws For Against Abstain Votes 65,592,186 24,302,176 3,454,611 The vote required to approve Proposal No. 6 to amend the Company’s Second Amended and Restated Bylaws, as amended, to allow the Board in its sole discretion to determine, from time to time, the number of directors constituting the Board was the affirmative vote of a majority of the 206,836,945 outstanding shares of the Company’s Common Stock entitled to vote as of the record date for the Annual Meeting. Accordingly, stockholders did not approve Proposal No. 6.
View on SEC.gov

637 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001851734-22-000643
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.